FORT COLLINS, Colo., Sept. 14 /PRNewswire/ -- InViragen, LLC, a biotechnology company dedicated to developing vaccines for emerging infectious diseases worldwide, has entered into an Exclusive Patent License Agreement with the Centers for Disease Control and Prevention (CDC). The announcement is made by Dr. Dan Stinchcomb, InViragen’s Chief Executive Officer, whose company received the Colorado Bioscience Association (CBSA)/ Colorado Office of Economic Development and International Trade’s Venture Showcase Award last year.
